Pedro J. Beltran, Ph.D.

Pedro J. Beltran, Ph.D., is BridgeBio Pharma’s Senior Vice President and Head of Biology for Oncology Therapeutics in South San Francisco, CA. Prior to joining BridgeBio, Pedro was Senior Vice President and Head of Biology at UNITY Biotechnology, a clinical stage company focused on halting and reversing diseases of aging, where his team of scientists discovered and developed a novel, intravitreal, Bcl-xL inhibitor for age-related macular degeneration (AMD) currently in Phase 1 clinical trials. Prior to Unity Biotechnology, Pedro was Executive Director, Discovery Research, at Amgen, Inc. Pedro was a member of the Immuno-Oncology Research Therapeutic Area Senior Leadership Team responsible for filling more than 10 INDs. Pedro’s key roles during his 14-yr tenure at Amgen included Global Discovery Research Leader for ganitumab (an anti-IGF-1R fully-human monoclonal antibody – Phase 3) and Imlygic® (the first oncolytic virus approved in the US for the treatment of melanoma). Previously, Pedro earned a B.S. in Molecular Biology from the Florida Institute of Technology, Melbourne, FL., and a Ph.D. in Cancer Biology from the laboratory of Dr. Isaiah J. Fidler at the University of Texas, M.D. Anderson Cancer Center. He was also a Lois Pope Post-doctoral Fellow in Neuroscience at the laboratory of Dr. John Bixby, University of Miami, School of Medicine. Pedro has authored more than 40 peer-reviewed manuscripts and 30+ scientific abstracts. He has also been an invited speaker to multiple international conferences and holds patents describing novel ways to treat malignant and aging diseases.